Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05070728 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert
A Phase 3 study, sponsored by EyePoint Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
NCT05070728: Clinical Trial Phase 3 study, sponsored by EyePoint Pharmaceuticals.
NCT05070728 is a Phase 3 study that was terminated before completion, run by EyePoint Pharmaceuticals. The registered enrollment target is 12 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05070728, a Phase 3 study, was terminated before completion, sponsored by EyePoint Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
Study Summary
A study to evaluate the safety and efficacy of a fluocinolone acetonide intravitreal (FAI) insert in the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye.
Primary Outcome
Recurrence was defined as: * An increase in the vitreous haze of ≥2 steps compared to baseline or any visit time point prior to the Week 24 visit; or * A deterioration in visual acuity of at least 15 letters BCVA compared to baseline or any visit time point prior to the Week 24 visit.
Interventions
- DRUG Sham Injector
- DRUG FAI Insert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-10-13 |
| Est. Completion | 2023-04-12 |
| Phase | Phase 3 |
Why NCT05070728 stopped before completion
NCT05070728 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham Injector is the first listed.
NCT05070728 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05070728 about?
NCT05070728 is a clinical study titled "Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert". A study to evaluate the safety and efficacy of a fluocinolone acetonide intravitreal (FAI) insert in the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye.
What is the current status of trial NCT05070728?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2021-10-13. Estimated completion is 2023-04-12.
What interventions are being tested in trial NCT05070728?
The interventions under investigation include: Sham Injector (DRUG), FAI Insert (DRUG).
Who is sponsoring clinical trial NCT05070728?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05070728's enrollment target sits among peer trials
12 1984th of 2000 higher than 12 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI